PwC Drops Weight Loss Drugs From Employee Benefits in the US

Why It Matters

The decision underscores how soaring GLP‑1 prices are forcing corporations to trim benefits, reshaping employee health coverage and cost structures across the market.

Key Takeaways

• PwC US limits GLP‑1 coverage to diabetes patients only
• Monthly GLP‑1 cost ~£300 ($380), driving benefit cuts
• Employer premiums can rise 14% when covering weight‑loss drugs
• Blue Cross Blue Shield already restricted its own employee coverage
• Trend may spread across Big Four and large corporations

Pulse Analysis

GLP‑1 medications such as Ozempic and Mounjaro have exploded in popularity for weight management, but their high price tags—about £300 per month, roughly $380—have turned them into a financial flashpoint for employers. While originally prescribed for type 2 diabetes, insurers and corporate health plans have broadened coverage to address the obesity epidemic, only to discover that the added cost can push insurance premiums upward by double‑digit percentages. This dynamic has prompted a reevaluation of what constitutes a core benefit versus an elective perk.

PwC’s latest benefit revision reflects that recalibration. Citing “rapidly rising costs,” the firm will now limit pharmacy coverage of GLP‑1 drugs to employees with a documented diabetes diagnosis, a policy that aligns with recent moves by Blue Cross Blue Shield, which also withdrew weight‑loss drug coverage for its staff. The change arrives as research shows that including these drugs can inflate employer premiums by as much as 14%, a burden many large organizations deem unsustainable. By narrowing eligibility, PwC aims to preserve access to clinically essential treatments while curbing expense growth.

The ripple effect could reshape employee health strategies across the Big Four and other Fortune‑500 firms. Companies may explore alternative wellness programs, negotiate drug pricing rebates, or shift focus toward preventive measures that reduce reliance on costly pharmaceuticals. As the market grapples with the balance between employee well‑being and fiscal responsibility, the trajectory of GLP‑1 coverage will likely serve as a bellwether for broader benefit design trends in the United States.